Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expert Discussion: HER2-Positive Breast Cancer.
Foukakis T, Matikas A, Oikonomidou O, Andreopoulou E, Mavroudis D. Foukakis T, et al. Among authors: andreopoulou e. Breast Care (Basel). 2021 Aug;16(4):422-428. doi: 10.1159/000516965. Epub 2021 Jun 17. Breast Care (Basel). 2021. PMID: 34602950 Free PMC article. No abstract available.
PARP Inhibitors in Breast Cancer: Why, How, and When?
Paradiso A, Andreopoulou E, Conte P, Eniu A, Saghatchian M. Paradiso A, et al. Among authors: andreopoulou e. Breast Care (Basel). 2018 Jul;13(3):216-219. doi: 10.1159/000490746. Epub 2018 Jun 20. Breast Care (Basel). 2018. PMID: 30069183 Free PMC article. No abstract available.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Kearney M, Franks L, Lee S, Tiersten A, Makower DF, Cigler T, Mundi P, Chi DC, Goel A, Klein P, Andreopoulou E, Sparano J, Trivedi M, Accordino M, Califano A, Hershman DL, Silva J, Kalinsky K. Kearney M, et al. Among authors: andreopoulou e. Breast Cancer Res Treat. 2021 Aug;189(1):177-185. doi: 10.1007/s10549-021-06306-4. Epub 2021 Jun 24. Breast Cancer Res Treat. 2021. PMID: 34169393 Free PMC article. Clinical Trial.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Adelson K, et al. Among authors: andreopoulou e. NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721390 Free PMC article.
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.
Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, Connolly E, Saenger Y, Kalinsky K. Marks DK, et al. Among authors: andreopoulou e. Front Oncol. 2020 Jun 16;10:968. doi: 10.3389/fonc.2020.00968. eCollection 2020. Front Oncol. 2020. PMID: 32612958 Free PMC article.
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Fasano GA, Bayard S, Chen Y, Varella L, Cigler T, Bensenhaver J, Simmons R, Swistel A, Marti J, Moore A, Andreopoulou E, Ng J, Brandmaier A, Formenti S, Ali H, Davis M, Newman L. Fasano GA, et al. Among authors: andreopoulou e. Breast Cancer Res Treat. 2022 Feb;192(1):163-173. doi: 10.1007/s10549-021-06481-4. Epub 2022 Jan 13. Breast Cancer Res Treat. 2022. PMID: 35022867
69 results